Allogeneic Hematopoietic Stem Cell Transplantation Cohort Study

Launched by RUIJIN HOSPITAL · Nov 24, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the outcomes of patients who have received or are about to receive a treatment called allogeneic hematopoietic stem cell transplantation. This is a procedure where stem cells from a donor are used to help treat certain blood disorders. The goal of the study is to collect real-world data about how patients do after the transplant, which can help improve future treatments and healthcare decisions.

To participate in the trial, you need to have had at least one visit to a stem cell transplant center since January 1, 2021, and you should be scheduled to undergo the transplant or have already had it. Unfortunately, people who have serious other health issues, struggle with addiction, or whose safety might be at risk will not be eligible to join. If you decide to participate, you can expect to provide information about your health and experiences, which will contribute to a better understanding of this treatment's effectiveness.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. At least one visit to a stem cell transplant center beginning January 1, 2021
• • 2. Proposed to undergo or have undergone hematopoietic stem cell transplantation
• Exclusion Criteria:
• • 1. Long-term follow-up information for patients not available for any reason (e.g., unavailable or with serious concomitant disease) according to investigator opinion
• • 2. Due to alcohol and drug addiction thus affecting their ability to follow the requirements of the study
• • 3. Presence of conditions that could jeopardize patient safety or affect their adherence to the protocol, according to the investigator's opinion